Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.24
- Piotroski Score 3.00
- Grade Neutral
- Symbol (RCEL)
- Company AVITA Medical, Inc.
- Price $12.87
- Changes Percentage (-1.38%)
- Change -$0.18
- Day Low $12.58
- Day High $13.45
- Year High $18.93
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $9.00
- High Stock Price Target $9.00
- Low Stock Price Target $9.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.76
- Trailing P/E Ratio -5.2
- Forward P/E Ratio -5.2
- P/E Growth -5.2
- Net Income $-39,168,218
Income Statement
Quarterly
Annual
Latest News of RCEL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
FC Barcelona Legend Xavi Makes Messi Inter Miami Reunion Decision, Reports SPORT
Former FC Barcelona player Xavi Hernandez could reunite with Lionel Messi at Inter Miami as head coach. Despite other candidates, Xavi's desire for a sabbatical may delay his return to coaching. His p...
By Forbes | 1 day ago -
La Liga drops plans to play Barcelona v Atlético fixture in Miami next month
La Liga has postponed plans to hold Barcelona vs. Atlético Madrid in the US but aims to host matches abroad in the future. Javier Tebas eyes 2025-26 season for potential games overseas, as other leag...
By The Guardian | 2 days ago -
FC Barcelona's Robert Lewandowski: 'Every Goal Gives Me More Power'
Robert Lewandowski, despite 20 years in professional soccer, maintains a passion for the game. His dedication, discipline, and long-term vision for life beyond soccer are evident in his approach to tr...
By Forbes | 2 days ago
